BioCryst Pharma (BCRX) Misses Q3 EPS by 3c
Tweet
Share
E-mailGet Alerts BCRX Hot Sheet
Price: $9.14 +1.67%
EPS Growth %: -13.3%
Financial Fact:
Product sales: 0
Today's EPS Names:
OCCI, MAYS, CRMT, More
EPS Growth %: -13.3%
Financial Fact:
Product sales: 0
Today's EPS Names:
OCCI, MAYS, CRMT, More
Join SI Premium – FREE
BioCryst Pharma (NASDAQ: BCRX) reported Q3 EPS of ($0.28), $0.03 worse than the analyst estimate of ($0.25). Revenue for the quarter came in at $1.5 million versus the consensus estimate of $3.77 million.
For earnings history and earnings-related data on BioCryst Pharma (BCRX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Goldman reinstates Estee Lauder rating, sees turnaround driving growth and margins
- Sun Communities names Ileana McAlary as general counsel and EVP
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
